|Bid||35.40 x N/A|
|Ask||37.80 x N/A|
|Day's Range||37.00 - 38.10|
|52 Week Range||34.00 - 163.00|
|Beta (5Y Monthly)||-0.10|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jun 03, 2012|
|1y Target Est||N/A|
Panaxia Global, the controlling owner of Panaxia Malta (operations) Ltd., a global pharma company that develops, manufactures and markets advanced medical cannabis products of pharmaceutical quality, announced today that it has received an official license from the health authorities in Malta to manufacture finished medical cannabis products.
Dr. Dadi Segal, CEO of Panaxia Israel: "We conclude 2021 with double-digit revenue growth, including export revenues of approximately 5.6 million and 8% market share in the oils category in Germany. It was a launching year and a market penetration of the first product we have exported, clinically repellent and clinically backed. We are proud that at such an early stage, about a year after we first started exporting our premium oils to Germany, Panaxia ranks #3 in cannabis oil sales in Germany. A
Panaxia Labs Israel Ltd. ("Panaxia Israel"), (TASE: PNAX), a global pharma company which develops, manufactures and markets progressive medical cannabis products in pharmaceutical quality, and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), announced today a first export of medical cannabis sublingual tablets from Israel to France.